GA
55 programs · 52 companies
Programs
55
Companies
52
Trials
52
MOAs
38
CDK2iFcRniBTKiSHP2iCDK4/6iTYK2iPARPiWEE1iKIF18AiVEGFi
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tirafotisoran | Phase 2 | CD38 | ||
| ABB-2476 | Phase 1/2 | USP1 | ||
| AZN-8281 | Phase 1 | SHP2 | ||
| Doxacagene | Approved | PSMA | ||
| Sovafutibatinib | Approved | FcRn | ||
| Adagracapivasertib | NDA/BLA | BET | ||
| BMR-1165 | Phase 2 | CD47 | ||
| LEG-6533 | NDA/BLA | VEGF | ||
| Talatuximab | Preclinical | CD3 | ||
| Talafotisoran | Phase 2/3 | IL-23 | ||
| RAR-5994 | Phase 2/3 | IL-13 | ||
| Rilunesiran | Phase 1/2 | GPRC5D | ||
| ETN-4807 | Phase 1/2 | APOC3 | ||
| Lisonesiran | NDA/BLA | CD47 | ||
| UCB-8638 | Phase 1 | SGLT2 | ||
| Rimainavolisib | Phase 3 | TYK2 | ||
| 460-4909 | Preclinical | PSMA | ||
| MAY-IIT-936 | Phase 3 | FLT3 | ||
| UCS-IIT-951 | Phase 2 | USP1 | ||
| Pexainavolisib | Approved | SOS1 | ||
| CGE-1556 | Phase 1 | KRASG12C | ||
| NKT-344 | Phase 1 | C5 | ||
| NKT-8115 | Phase 2 | SGLT2 | ||
| LUC-2815 | Phase 1 | PCSK9 | ||
| Rilucapivasertib | Phase 2/3 | CDK2 | ||
| TUR-1584 | Phase 2/3 | FLT3 | ||
| Polarapivir | NDA/BLA | FcRn | ||
| AER-8916 | Approved | CD47 | ||
| Tixatuximab | Phase 2 | Tau | ||
| ALE-9377 | Approved | CD19 | ||
| Mirilemzoparlimab | Phase 2 | CD20 | ||
| SHI-2989 | Phase 2 | AHR | ||
| LAE-3866 | Phase 1/2 | FXIa | ||
| 000-7991 | Phase 1 | FXIa | ||
| GC-7403 | Phase 2/3 | PI3Kα | ||
| Doxazanubrutinib | Phase 3 | PARP | ||
| TOT-3942 | Preclinical | PI3Kα | ||
| Zorizumab | Phase 1/2 | EGFR | ||
| Niraglumide | Phase 2 | WEE1 | ||
| LPC-4508 | Phase 1 | PSMA | ||
| Rimarapivir | Phase 3 | PSMA | ||
| Gozesertib | Phase 1/2 | CDK2 | ||
| Olpazasiran | Phase 3 | FcRn | ||
| Tixasotorasib | Preclinical | BCMA | ||
| CYA-8318 | Preclinical | MET | ||
| Daracilimab | Preclinical | IL-23 | ||
| Liracapivasertib | Phase 1 | GIP-R | ||
| Tezesacituzumab | Phase 2 | C5 | ||
| Liravorutinib | Approved | CD47 | ||
| AIP-1890 | Phase 3 | DLL3 | ||
| Tixacilimab | Phase 2/3 | CD3 | ||
| TAT-IIT-583 | Phase 3 | Menin | ||
| Voxatenlimab | Approved | PI3Kα | ||
| WST-3903 | Preclinical | FXIa | ||
| Cevisotorasib | Phase 2/3 | HER2 |
Trials (52)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT03620071 | Tirafotisoran | Phase 2 | Active |
| NCT04854579 | Tirafotisoran | Phase 2 | Terminated |
| NCT08784503 | ABB-2476 | Phase 1/2 | Recruiting |
| NCT03938245 | ABB-2476 | Phase 1/2 | Completed |
| NCT05448992 | AZN-8281 | Phase 1 | Completed |
| NCT05314781 | AZN-8281 | Phase 1 | Not yet recr... |
| NCT06054301 | Doxacagene | Approved | Not yet recr... |
| NCT04308439 | BMR-1165 | Phase 2 | Not yet recr... |
| NCT05235517 | Talafotisoran | Phase 2/3 | Active |
| NCT06970166 | Talafotisoran | Phase 2/3 | Terminated |
| NCT07110862 | RAR-5994 | Phase 2/3 | Recruiting |
| NCT07193676 | Rilunesiran | Phase 1/2 | Terminated |
| NCT04625722 | Rilunesiran | Phase 1/2 | Completed |
| NCT04356679 | ETN-4807 | Phase 1/2 | Terminated |
| NCT06098725 | Lisonesiran | NDA/BLA | Active |
| NCT03460113 | Lisonesiran | NDA/BLA | Recruiting |
| NCT08404777 | UCB-8638 | Phase 1 | Recruiting |
| NCT04413741 | UCB-8638 | Phase 1 | Terminated |
| NCT04113519 | Rimainavolisib | Phase 3 | Recruiting |
| NCT05959987 | Rimainavolisib | Phase 3 | Terminated |